By Joe O’Connell, MD, Vice President and Global Therapeutic Head for Hematology/Oncology, inVentiv Health
At the annual American Society of Clinical Oncology (ASCO) meeting, the focus was significantly on targeted therapies, with studies demonstrating significant – and potentially practice-changing – results. Of the four abstracts discussed during Sunday’s Plenary Session, which features abstracts deemed to have the greatest potential to impact patient care, three were about targeted therapies. The fourth one was about the potential of digital transformation in cancer care to impact survival and other patient-reported outcomes. In addition, attention was higher than ever on issues related to clinical trial design and the use of Real-World Evidence (RWE) to both establish efficacy and support the best position for new drugs in emerging clinical pathways.